1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5–29.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Lim MC, Moon EK, Shin A, Jung KW, Won YJ, Seo SS, et al. Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010. J Gynecol Oncol. 2013; 24:298–302.
![crossref](/image/icon/bnr_ref_cross.gif)
3. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014; 384:1376–88.
![crossref](/image/icon/bnr_ref_cross.gif)
4. Ahluwalia A, Yan P, Hurteau JA, Bigsby RM, Jung SH, Huang TH, et al. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol. 2001; 82:261–8.
5. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004; 351:2519–29.
![crossref](/image/icon/bnr_ref_cross.gif)
6. Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ. Ten-year follow-up of ovarian cancer patients after secondlook laparotomy with negative findings. Obstet Gynecol. 1999; 93:21–4.
![crossref](/image/icon/bnr_ref_cross.gif)
7. Vaidya AP, Curtin JP. The follow-up of ovarian cancer. Semin Oncol. 2003; 30:401–12.
![crossref](/image/icon/bnr_ref_cross.gif)
8. Matsuo K, Sheridan TB, Yoshino K, Miyake T, Hew KE, Im DD, et al. Significance of lymphovascular space invasion in epithelial ovarian cancer. Cancer Med. 2012; 1:156–64.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Lim MC, Lee JS, Nam BH, Seo SS, Kang S, Park SY. Lower extremity edema in patients with early ovarian cancer. J Ovarian Res. 2014; 7:28.
![crossref](/image/icon/bnr_ref_cross.gif)
10. Kim SI, Lim MC, Lee JS, Lee Y, Park K, Joo J, et al. Impact of lower limb lymphedema on quality of life in gynecologic cancer survivors after pelvic lymph node dissection. Eur J Obstet Gynecol Reprod Biol. 2015; 192:31–6.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Swanton C, Caldas C. Molecular classification of solid tumours: towards pathway-driven therapeutics. Br J Cancer. 2009; 100:1517–22.
![crossref](/image/icon/bnr_ref_cross.gif)
12. Cardin V, Friston KJ, Zeki S. Top-down modulations in the visual form pathway revealed with dynamic causal modeling. Cereb Cortex. 2011; 21:550–62.
![crossref](/image/icon/bnr_ref_cross.gif)
13. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature. 2008; 452:553–63.
![crossref](/image/icon/bnr_ref_cross.gif)
14. Hanash S. Integrated global profiling of cancer. Nat Rev Cancer. 2004; 4:638–44.
![crossref](/image/icon/bnr_ref_cross.gif)
15. Dettling M, Buhlmann P. Boosting for tumor classification with gene expression data. Bioinformatics. 2003; 19:1061–9.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Vapnik VN. An overview of statistical learning theory. IEEE Trans Neural Netw. 1999; 10:988–99.
![crossref](/image/icon/bnr_ref_cross.gif)
17. Furey TS, Cristianini N, Duffy N, Bednarski DW, Schummer M, Haussler D. Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics. 2000; 16:906–14.
![crossref](/image/icon/bnr_ref_cross.gif)
18. Ishwaran H, Kogalur UB. Consistency of random survival forests. Stat Probab Lett. 2010; 80:1056–64.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Drier Y, Sheffer M, Domany E. Pathway-based personalized analysis of cancer. Proc Natl Acad Sci U S A. 2013; 110:6388–93.
![crossref](/image/icon/bnr_ref_cross.gif)
20. Hastie T, Stuetzle W. Principal curves. J Am Stat Assoc. 1989; 84:502–16.
![crossref](/image/icon/bnr_ref_cross.gif)
21. Choi CH, Choi JJ, Park YA, Lee YY, Song SY, Sung CO, et al. Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival. Br J Cancer. 2012; 107:91–9.
![crossref](/image/icon/bnr_ref_cross.gif)
22. Ganzfried BF, Riester M, Haibe-Kains B, Risch T, Tyekucheva S, Jazic I, et al. curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database (Oxford). 2013; 2013:bat013.
![crossref](/image/icon/bnr_ref_cross.gif)
23. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15:361–87.
![crossref](/image/icon/bnr_ref_cross.gif)
24. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glio-blastoma genes and core pathways. Nature. 2008; 455:1061–8.
25. Bibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, Wu B, et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res. 2006; 16:383–93.
![crossref](/image/icon/bnr_ref_cross.gif)
26. Riggio AI, Blyth K. The enigmatic role of RUNX1 in female-related cancers: current knowledge & future perspectives. FEBS J. 2017; 284:2345–62.
27. Gurbuz I, Chiquet-Ehrismann R. CCN4/WISP1 (WNT1 inducible signaling pathway protein 1): a focus on its role in cancer. Int J Biochem Cell Biol. 2015; 62:142–6.
![crossref](/image/icon/bnr_ref_cross.gif)
28. Davies SR, Watkins G, Mansel RE, Jiang WG. Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer. Ann Surg Oncol. 2007; 14:1909–18.
![crossref](/image/icon/bnr_ref_cross.gif)
29. Riccardo F, Arigoni M, Buson G, Zago E, Iezzi M, Longo D, et al. Characterization of a genetic mouse model of lung cancer: a promise to identify non-small cell lung cancer therapeutic targets and biomarkers. BMC Genomics. 2014; 15 Suppl 3:S1.
![crossref](/image/icon/bnr_ref_cross.gif)
30. Feng N, Ching T, Wang Y, Liu B, Lin H, Shi O, et al. Analysis of microarraydata on gene expression and methylation to identify long non-coding RNAs in non-small cell lung cancer. Sci Rep. 2016; 6:37233.
![crossref](/image/icon/bnr_ref_cross.gif)